公开(公告)号：US20230159439A1

公开(公告)日：2023-05-25

申请号：US17832385

申请日：2022-06-03

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Hans Peter Nestler ,  Ingrid Mechin ,  Joseph Kim ,  Martin Smrcina ,  Nina Ma ,  Ronghua Li ,  Ryan Hartung ,  William Bock ,  Bertrand Vivet

IPC: C07C235/66 ,  A61K45/06 ,  A61K31/197 ,  C07C323/19 ,  C07D215/48 ,  A61K31/47 ,  C07C309/75 ,  C07D333/70 ,  A61K31/381 ,  C07C309/68 ,  C07D277/64 ,  A61K31/428 ,  C07D417/12 ,  A61K31/4709 ,  C07D307/79 ,  A61K31/343 ,  C07D471/04 ,  A61K31/437 ,  C07D239/70 ,  A61K31/517 ,  C07D239/88

CPC classification number: C07C235/66 ,  A61K45/06 ,  A61K31/197 ,  C07C323/19 ,  C07D215/48 ,  A61K31/47 ,  C07C309/75 ,  C07D333/70 ,  A61K31/381 ,  C07C309/68 ,  C07D277/64 ,  A61K31/428 ,  C07D417/12 ,  A61K31/4709 ,  C07D307/79 ,  A61K31/343 ,  C07D471/04 ,  A61K31/437 ,  C07D239/70 ,  A61K31/517 ,  C07D239/88 ,  C07C2603/74 ,  C07C2601/14

Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20230147360A1

公开(公告)日：2023-05-11

申请号：US17832388

申请日：2022-06-03

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Hans Peter Nestler ,  Ingrid Mechin ,  Martin Smrcina ,  Ronghua Li ,  Ryan Hartung ,  William Bock ,  Bertrand Vivet ,  Andrew Scholte

IPC: C07D333/54 ,  C07D417/12 ,  C07D333/64 ,  C07D417/04 ,  C07D277/64 ,  A61K45/06

CPC classification number: C07D333/54 ,  C07D417/12 ,  C07D333/64 ,  C07D417/04 ,  C07D277/64 ,  A61K45/06

Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20240002374A1

公开(公告)日：2024-01-04

申请号：US17742169

申请日：2022-05-11

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Sylvie Baltzer ,  Bertrand Vivet ,  Brian Freed ,  Hans Peter Nestler ,  Helen Yeoman ,  Ingrid Mechin ,  Martin Smrcina ,  Nina Ma ,  Sylvain Lebreton ,  Ryan Hartung ,  William Wire ,  Sukanthini Thurairatnam

IPC: C07D417/12 ,  C07D277/52 ,  C07D417/04 ,  C07D417/14 ,  C07F9/22 ,  C07D498/10

CPC classification number: C07D417/12 ,  C07D277/52 ,  C07D498/10 ,  C07D417/14 ,  C07F9/222 ,  C07D417/04

Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20230159438A1

公开(公告)日：2023-05-25

申请号：US17832384

申请日：2022-06-03

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Zhongli Gao ,  Gregory Hurlbut ,  Hans Peter Nestler ,  Helen Yeoman ,  Martin Smrcina ,  Ronghua Li ,  Ryan Hartung ,  William Wire ,  Bertrand Vivet ,  Nina Ma

IPC: C07C235/66 ,  C07D231/12 ,  C07D317/54 ,  C07C317/14 ,  C07C321/28 ,  C07D277/24 ,  C07D213/30 ,  C07D261/08 ,  C07D277/64 ,  C07D277/30 ,  C07D305/06 ,  A61K31/198 ,  A61K31/415 ,  A61K31/36 ,  A61K31/426 ,  A61K31/44 ,  A61K31/42 ,  A61K31/428 ,  A61K31/337 ,  A61K45/06

CPC classification number: C07C235/66 ,  C07D231/12 ,  C07D317/54 ,  C07C317/14 ,  C07C321/28 ,  C07D277/24 ,  C07D213/30 ,  C07D261/08 ,  C07D277/64 ,  C07D277/30 ,  C07D305/06 ,  A61K31/198 ,  A61K31/415 ,  A61K31/36 ,  A61K31/426 ,  A61K31/44 ,  A61K31/42 ,  A61K31/428 ,  A61K31/337 ,  A61K45/06 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/10

Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20240279220A1

公开(公告)日：2024-08-22

申请号：US18593686

申请日：2024-03-01

Applicant: Genzyme Corporation

Inventor： Junkai Liao ,  Mark Munson ,  Sukanthini Thurairatnam ,  Bradford Hirth ,  Zhongli Gao ,  Gregory Hurlbut ,  David Borcherding ,  Matthieu Barrague ,  Timothy Alan Gillespy ,  Alexandre Gross ,  Andrew Good ,  Roy Vaz ,  Jinyu Liu ,  Yi Li ,  Markus Metz ,  Anatoly Ruvinsky ,  Claude Barberis

IPC: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/6503

CPC classification number: C07D417/14 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/675 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07F9/65031

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20240239784A1

公开(公告)日：2024-07-18

申请号：US18593643

申请日：2024-03-01

Applicant: GENZYME CORPORATION

Inventor： Junkai Liao ,  Mark Munson ,  Sukanthini Thurairatnam ,  Bradford Hirth ,  Zhongli Gao ,  Gregory Hurlbut ,  David Borcherding ,  Matthieu Barrague ,  Timothy Alan Gillespy ,  Alexandre Gross ,  Thaddeus Nieduzak ,  Andrew Good ,  Roy Vaz ,  Jinyu Liu ,  Yi Li ,  Markus Metz ,  Anatoly Ruvinsky ,  Michael Kothe

IPC: C07D413/14 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D471/04

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

公开(公告)号：US20230137585A1

公开(公告)日：2023-05-04

申请号：US17742172

申请日：2022-05-11

Applicant: Genzyme Corporation

Inventor： Zhongli Gao ,  Gregory Hurlbut ,  Mark Munson ,  Junkai Liao

IPC: C07D239/69 ,  C07D241/22 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D213/76 ,  C07D401/14 ,  C07D401/12 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/444 ,  A61K31/4418 ,  A61K31/4545 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  A61P11/00

Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.